VEGFR3 tyrosine kinase inhibition aggravates cisplatin nephrotoxicity

Am J Physiol Renal Physiol. 2021 Dec 1;321(6):F675-F688. doi: 10.1152/ajprenal.00186.2021. Epub 2021 Oct 18.

Abstract

Expansion of renal lymphatic networks, or lymphangiogenesis (LA), is well recognized during development and is now being implicated in kidney diseases. Although LA is associated with multiple pathological conditions, very little is known about its role in acute kidney injury. The purpose of this study was to evaluate the role of LA in a model of cisplatin-induced nephrotoxicity. LA is predominately regulated by vascular endothelial growth factor (VEGF)-C and VEGF-D, ligands that exert their function through their cognate receptor VEGF receptor 3 (VEGFR3). We demonstrated that use of MAZ51, a selective VEGFR3 inhibitor, caused significantly worse structural and functional kidney damage in cisplatin nephrotoxicity. Apoptotic cell death and inflammation were also increased in MAZ51-treated animals compared with vehicle-treated animals following cisplatin administration. Notably, MAZ51 caused significant upregulation of intrarenal phospho-NF-κB, phospho-JNK, and IL-6. Cisplatin nephrotoxicity is associated with vascular congestion due to endothelial dysfunction. Using three-dimensional tissue cytometry, a novel approach to explore lymphatics in the kidney, we detected significant vascular autofluorescence attributed to erythrocytes in cisplatin alone-treated animals. Interestingly, no such congestion was detected in MAZ51-treated animals. We found increased renal vascular damage in MAZ51-treated animals, whereby MAZ51 caused a modest decrease in the endothelial markers endomucin and von Willebrand factor, with a modest increase in VEGFR2. Our findings identify a protective role for de novo LA in cisplatin nephrotoxicity and provide a rationale for the development of therapeutic approaches targeting LA. Our study also suggests off-target effects of MAZ51 on the vasculature in the setting of cisplatin nephrotoxicity.NEW & NOTEWORTHY Little is known about injury-associated LA in the kidney and its role in the pathophysiology of acute kidney injury (AKI). Observed exacerbation of cisplatin-induced AKI after LA inhibition was accompanied by increased medullary damage and cell death in the kidney. LA inhibition also upregulated compensatory expression of LA regulatory proteins, including JNK and NF-κB. These data support the premise that LA is induced during AKI and lymphatic expansion is a protective mechanism in cisplatin nephrotoxicity.

Keywords: kidney; lymphangiogenesis; lymphatics; three-dimensional imaging; vascular endothelial growth factor receptor 3.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cisplatin
  • Disease Models, Animal
  • Indoles / toxicity*
  • Inflammation Mediators / metabolism
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Kidney / drug effects*
  • Kidney / enzymology
  • Kidney / pathology
  • Kidney / physiopathology
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / enzymology
  • Kidney Diseases / pathology
  • Kidney Diseases / physiopathology
  • Lymphangiogenesis / drug effects*
  • Lymphatic Vessels / drug effects*
  • Lymphatic Vessels / enzymology
  • Lymphatic Vessels / pathology
  • Lymphatic Vessels / physiopathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • NF-kappa B / metabolism
  • Naphthalenes / toxicity*
  • Phosphorylation
  • Protein Kinase Inhibitors / toxicity*
  • Signal Transduction
  • Vascular Endothelial Growth Factor Receptor-3 / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor Receptor-3 / metabolism

Substances

  • 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one
  • Indoles
  • Inflammation Mediators
  • Interleukin-6
  • NF-kappa B
  • Naphthalenes
  • Protein Kinase Inhibitors
  • interleukin-6, mouse
  • Vascular Endothelial Growth Factor Receptor-3
  • JNK Mitogen-Activated Protein Kinases
  • Cisplatin

Associated data

  • figshare/10.6084/m9.figshare.16553616.v2
  • figshare/10.6084/m9.figshare.14569437.v2
  • figshare/10.6084/m9.figshare.14569449.v2